1-2 of 2
David Perol
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial

Allison Voisin, Catherine Terret, Camille Schiffler, Anne-Sophie Bidaux, Hélène Vanacker, Marlène Perrin-Niquet, Maud Barbery, Armelle Vinceneux, Lauriane Eberst, Pierre Stéphan, Gwenaële Garin, Dany Spaggiari, David Pérol, Yenkel Grinberg-Bleyer, Philippe A. Cassier
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2111–2120.
https://doi.org/10.1158/1078-0432.CCR-23-2893
Published: 15 May 2024
View article titled, Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial
Open the PDF for Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial in another window
Includes: Supplementary data
Journal Articles

Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer

Sylvie Négrier, David Perol, Alain Ravaud, Jacques O. Bay, Stéphane Oudard, Sylvie Chabaud, Pierre Fargeot, Remy Delva, Gael Deplanque, Gwenaelle Gravis, Bernard Escudier, for the French Immunotherapy Group
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (18): 5907–5912.
https://doi.org/10.1158/1078-0432.CCR-08-0236
Published: 14 September 2008
View article titled, Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer
Open the PDF for Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNα in Patients with Good Prognosis Metastatic Renal Cancer in another window